Brimonidine in Rosacea
Efficacy and Safety of Combining Doxycycline With Pulsed Dye Laser Versus Topical Brimonidine 0.33% in the Treatment of Erythematotelangiectatic Rosacea: a Comparative Clinical and Dermoscopic Study
1 other identifier
interventional
45
0 countries
N/A
Brief Summary
Rosacea is a chronic and relapsing inflammatory cutaneous disorder with highly variable prevalence worldwide.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2022
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2022
CompletedStudy Start
First participant enrolled
May 25, 2022
CompletedFirst Posted
Study publicly available on registry
June 2, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 15, 2022
CompletedJune 2, 2022
June 1, 2022
4 months
May 20, 2022
June 1, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Clinical erythema assessment scale
clinical scale
3 months
Secondary Outcomes (1)
Thickness of capillaries by dermoscope
3 months
Study Arms (3)
Pulsed dye laser
ACTIVE COMPARATORLaser
Doxycycline
ACTIVE COMPARATORDrug
Brimonidine gel 0.33%
ACTIVE COMPARATORTopical drug
Interventions
Eligibility Criteria
You may qualify if:
- Patient with current erythematotelangiectatic rosacea
You may not qualify if:
- \- Pregnant females. 2-Patients on systemic steroids. 3-Patients complaining of other dermatological disorders mainly photosensitive cutaneous disorder.
- Patients receiving any systemic treatment including retinoids for the previous 1 month or any topical treatment for the previous 2 weeks or any laser sessions for the previous 3months for erythematotelangiectatic rosacea at least.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
May 20, 2022
First Posted
June 2, 2022
Study Start
May 25, 2022
Primary Completion
September 15, 2022
Study Completion
September 15, 2022
Last Updated
June 2, 2022
Record last verified: 2022-06